It is estimated that in the United States 11% of the population suffer from a chronic digestive disease, with a prevalence rate as high as 35% for those 65 years and over. These include conditions of the gastrointestinal tract that are chronic and relapsing. Two main types are Crohn’s disease and ulcerative colitis. Both forms have similar symptoms, i.e. diarrhea, abdomen pain, and weight loss. These conditions are traditionally treated with corticosteroids, immunomodulators, or biologic agents. Researchers continue to identify alternative treatment options that are efficacious and safe. Over the past several years, research evaluating the efficacy of CBD in gastrointestinal disorders has been mixed. Studies have shown that CBD has a positive impact on IBD conditions, specifically through an anti-inflammatory effect. Evidence shows that the activation and inhibition of peripheral and central cannabinoid receptors can affect processes of the GI tract. CBD may be a beneficial form of treatment due to the increased rate of clinical response without the traditional side effects reported with other treatment modalities.